Market Overview

West Pharmaceutical Services Warns On FY14, CEO To Retire

Related WST
Benzinga's Top Upgrades, Downgrades For September 15, 2017
The Market In 5 Minutes

West Pharmaceutical Services Inc. (NYSE: WST) fell sharply after it predicted full-year profits below expectations and said its chief executive will retire next year.

The Exton, Pennsylvania-based manufacturer of packaging and drug-delivery systems put third-quarter earnings in line with analysts' forecasts but said full-year results will be between $1.77 and $1.82 per share, versus analysts expectations of $1.84 per share.

Full-year profits will be hurt by $0.04 per share from a stronger dollar as well as by tax-rate changes "attributed to the geographic mix of our earnings," the company said.

In July, West Pharmaceutical had forecast full-year earnings of $1.77 to $1.89 per share and cut its sales outlook to between $1.43 billion and $1.46 billion from an earlier estimate of $1.45 billion to $1.48 billion.

West Pharmaceutical said Wednesday it hired a search firm to recruit a replacement for Chief Executive Donald E. Morel Jr., who will retire in May 2015. Morel was named to his current position in 2002 after 10 years with the company.

West Pharmaceutical began to rebound shortly after the open and traded recently at $44.86, down 1.1 percent.

Posted-In: News Guidance Movers


Related Articles (WST)

View Comments and Join the Discussion!